Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Esomeprazole.

C M Spencer1, D Faulds

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 13, 2000
PubMed
Summary
This summary is machine-generated.

Esomeprazole, a single-isomer proton pump inhibitor, offers superior intragastric pH control and improved healing rates for erosive esophagitis compared to omeprazole in patients with gastro-esophageal reflux disease (GORD). It also shows efficacy in H. pylori eradication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quetiapine : A Review of its Use in Schizophrenia.

CNS drugs·2016
Same author

The Yin and Yang of inflammation.

Current molecular medicine·2014
Same author

Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells.

Mucosal immunology·2014
Same author

Lanoteplase.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sdz asm 981.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Esomeprazole is the S-isomer of omeprazole, representing the first single-isomer proton pump inhibitor.
  • Gastro-esophageal reflux disease (GORD) is a common condition requiring effective acid suppression and symptom management.

Purpose of the Study:

  • To evaluate the efficacy of esomeprazole in controlling intragastric pH.
  • To compare the healing rates of erosive esophagitis and symptom control of esomeprazole versus omeprazole in GORD patients.
  • To assess the long-term healing maintenance and on-demand symptom control of esomeprazole in GORD.
  • To determine the effectiveness of esomeprazole-based triple therapy for Helicobacter pylori eradication.

Main Methods:

  • Randomized, double-blind, multicenter trials were conducted in patients with GORD and healthy volunteers.

Related Experiment Videos

  • Comparisons included esomeprazole versus omeprazole, lansoprazole, and pantoprazole for pH control.
  • Healing rates and symptom control were assessed over 8-week and 6-month periods.
  • Efficacy of esomeprazole-based triple therapy for H. pylori eradication was evaluated in multiple trials.

    • Main Results:

    • Esomeprazole demonstrated superior intragastric pH control compared to other proton pump inhibitors.
    • Higher healing rates of erosive esophagitis and better symptom control were observed with esomeprazole versus omeprazole.
    • Esomeprazole maintained healing of erosive esophagitis in 90% of patients and effectively controlled GORD symptoms on demand.
    • Esomeprazole-based triple therapy achieved H. pylori eradication comparable to longer omeprazole regimens and was more effective than esomeprazole plus clarithromycin in some regimens.

    Conclusions:

    • Esomeprazole offers significant advantages in managing GORD, including superior acid control and healing efficacy.
    • It provides effective long-term maintenance of healing and on-demand symptom relief for GORD patients.
    • Esomeprazole-based therapies are effective for H. pylori eradication, offering flexible treatment durations.